OrbiMed attracts $3.5bn across three healthcare funds
OrbiMed saw $3.5 billion in fresh investor commitments in its latest private investment fund offerings from a broad range of medical institutions, university endowments, foundations, pension funds and sovereign wealth funds.
Three fund closures were reported by officials this week with OrbiMed Private Investments VIII attracting $1.5 billion in capital, $800 million for OrbiMed Asia Partners IV and $1.2 billion for OrbiMed Royalty & Credit Opportunities III.
As observed within the Alternatives Watch healthcare beat, OrbiMed has been an active investor on many fronts in recent months. Where appropriate, the firm invests across multiple funds bringing potential investment amounts to upwards of $250 million per portfolio company. Some of this investment work of course has been focused in Asia, where the firm was among the Series C investors in Gracell Biotechnologies last year.
With a focus on China and India, OrbiMed Asia Partners IV allocates in venture capital deals through growth stage across biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services. The investments range from $10 million to $100 million with the fund’s holdings spanning across 20 portfolio companies.
OrbiMed Private Investments VIII, meanwhile, invests in venture capital opportunities in North America and Europe with a focus on biotechnology, medical device and diagnostics companies in targeted investments ranging from $10 million to $100 million across 40 portfolio companies.
Lastly, OrbiMed Royalty & Credit Opportunities III puts capital to work globally through structured credit and royalty monetization financing solutions aimed at healthcare companies and institutions. The investment range is from $10 million to $150 million per opportunity.
The new fund commitments bring the firm’s AUM to $18 billion across public equity, private equity and credit/royalty strategies. OrbiMed seeks to partner with healthcare companies across their life cycle from start-up seed capital through to growth equity and non-dilutive debt capital.
